New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TEVA;NPSP;CELG;AZN;ACOR;PFE;ALKS;PRXL;MEDI From The Last 14 Days
Check below for free stories on TEVA;NPSP;CELG;AZN;ACOR;PFE;ALKS;PRXL;MEDI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 25, 2014
07:14 EDTTEVATeva August weekly volatility elevated into Q2 and outlook
Teva August weekly call option implied volatility is at 34, August is at 25, September and January is at 22; compared to its 26-week average of 27 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 31.
07:06 EDTCELGCelgene shares should recover, says Cantor
Subscribe for More Information
July 24, 2014
12:20 EDTCELGCelgene price target raised to $115 from $85 at Piper Jaffray
Subscribe for More Information
07:45 EDTCELGCelgene reports Q2 VIDAZA sales decreased 28%
Subscribe for More Information
07:43 EDTCELGCelgene reports Q2 ABRAXANE sales increased 39%
Subscribe for More Information
07:42 EDTCELGCelgene reports Q2 REVLIMID sales increased 15%
Subscribe for More Information
07:34 EDTCELGCelgene raises FY14 adjusted EPS view to $3.60-$3.65 from $3.50-$3.60
Consensus is $3.67. Raises FY14 revenue view to $7.6B from $7.5B, consensus $7.54B. Sees Revlimid net product sales $4.95B from preview $4.9B-$5B range. Sees Abraxane net product sales $850M-$900M.
07:32 EDTCELGCelgene reports Q2 adjusted EPS 90c, consensus 89c
Reports Q2 revenue $1.87B, consensus $1.85B.
07:27 EDTTEVASome of Teva's biggest investors to vote against re-electing directors, WSJ says
Subscribe for More Information
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
July 23, 2014
15:30 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use